This trial will study the effects of MYK-224, given either as a single dose or multiple doses, on healthy adult Japanese participants.
3 Primary · 26 Secondary · Reporting Duration: Up to 130 days
Experimental Treatment
36 Total Participants · 4 Treatment Groups
Primary Treatment: MYK-224 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 60 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
18 - 65 | 100.0% |
Local Institution | 100.0% |
Met criteria | 100.0% |